Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)
Status:
Completed
Trial end date:
2020-05-24
Target enrollment:
Participant gender:
Summary
This is a randomized, rt-PA controlled, open-label phase 3 clinical study to evaluate the
efficacy and safety of recombinant human urokinase(rhPro-UK) versus rt-PA thrombolysis for
patients with acute ischaemic stroke in 4.5 hours after stroke onset.
Phase:
Phase 3
Details
Lead Sponsor:
Tasly Biopharmaceuticals Co., Ltd. Tasly Pharmaceuticals, Inc.